September 2024 FDA Roundup: Key Decisions Drive Oncology Forward
In September 2024, the FDA made several significant strides in oncology. Notably, the agency approved a subcutaneous formulation of atezolizumab (Tecentriq) for various cancer types, offering a more convenient administration option for patients. …